Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : DZ Bank reiterates its Sell rating

10/09/2020 | 06:09am EST

In a research note published by Elmar Kraus, DZ Bank advises its customers to Sell the stock.


© MarketScreener with dpa-AFX Analyser 2020
All news about NOVO NORDISK A/S
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
AQ
11/12NOVO NORDISK A/S : set to acquire Emisphere for $1.8 billion
AQ
11/09NOVO NORDISK A/S : to acquire Emisphere Technologies and obtain ownership of the..
AQ
11/09NOVO NORDISK : UBS reiterates its Neutral rating
MD
More news
Financials
Sales 2020 127 B 20 440 M 20 440 M
Net income 2020 42 174 M 6 766 M 6 766 M
Net cash 2020 8 472 M 1 359 M 1 359 M
P/E ratio 2020 22,9x
Yield 2020 2,17%
Capitalization 960 B 154 B 154 B
EV / Sales 2020 7,47x
EV / Sales 2021 7,01x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 414,75 DKK
Spread / Highest target 31,4%
Spread / Average Target 6,01%
Spread / Lowest Target -30,1%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.27%153 607
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555